Partners say their plant-based technology platform was validated.
Integrated BioPharma (INB) and the Fraunhofer USA Center for Molecular Biotechnology (FCMB) report the successful validation of their plant-based technology platform for the production of human therapeutic proteins and their further agreement to now use it to engineer and produce vaccines against influenza.
The AIPwLV™ platform was developed for INB by FCMB over the last three years. It uses nongenetically modified plants as a medium for the production of vaccine antigens.
“Unlike vaccine technologies currently in use,” points out Vidadi Yusibov, executive director of FCMB, “the AIPwLV platform enables practically limitless scalability of production of target antigens for vaccines against diseases, such as influenza, relatively quickly after identification of the active strain thereby significantly increasing the availability of efficacious vaccines for large-scale inoculations.”
